Friederike Pastore

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.

Journal: Leukemia research
Published: July 06, 2023

Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.

Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.

Journal: British journal of haematology
Published: April 15, 2023

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 12, 2023

Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis.

Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis.

Journal: Cancer
Published: June 28, 2022

Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome.

Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome.

Journal: Annals of hematology
Published: May 23, 2022

PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.

PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.

Journal: Cancer discovery
Published: January 08, 2020

JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.

JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.

Journal: Blood advances
Published: November 26, 2019

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Journal: Blood advances
Published: July 12, 2018

Targeting the CALR interactome in myeloproliferative neoplasms.

Targeting the CALR interactome in myeloproliferative neoplasms.

Journal: JCI insight
Published: June 05, 2018

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.

Journal: Blood advances
Published: January 31, 2018

Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.

Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 11, 2017

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Journal: Nature medicine
Published: June 11, 2016
Showing 1-12 of 20

Last Updated: 09/26/2026